Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Research Grant, 2014
    Increasing Glucocerebrosidase Activity as a Therapeutic Strategy

    Objective/Rationale:             
    Mutations in GBA1, the gene encoding the protein glucocerebrosidase, represent a common genetic risk factor for developing Parkinson disease (PD). PD patients with and...

  • Therapeutic Pipeline Program, 2014
    Development of a mGluR4 Therapeutic for Parkinson's Disease

    Study Rationale: 
    One of the major objectives for the development of new treatments for Parkinson’s disease is to find alternatives to the stimulation of the dopaminergic system through levodopa and...

  • Target Validation, 2014
    Role of Kinase Fyn in Levodopa-induced Dyskinesia

    Study Rationale:
    Levodopa frequently induces dyskinesia, an abnormal involuntary movement. In our laboratory we study how and where the prolonged use of levodopa modifies the brain of pre-clinical...

  • Rapid Response Innovation Awards, 2014
    Inhibition of Retinoic Acid Metabolism for the Treatment of Parkinson’s Disease

    Study Rationale:  
    Several lines of evidence point to the therapeutic potential of Retinoic acid (RA), a metabolite of vitamin A, in the treatment of Parkinson’s disease. For example, RA treatment...

  • LRRK2 Challenge, 2014
    Role of LRRK2 in the Regulation of Dopamine Receptor Trafficking

    Study Rationale:
    Mutation of the LRRK2 gene is the greatest known genetic contributor to Parkinson’s disease. However, the molecular mechanisms and pathological pathways by which LRRK2 induces neuronal...

  • Therapeutic Pipeline Program, 2014
    Cell Assays to Measure Peripheral Response to GCase Activators

    Objective/Rationale:             
    Individuals who carry one copy of the gene for Gaucher’s disease are at significantly increased risk of Parkinson’s disease. Lysosomal Therapeutics Inc. (LTI) is...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.